Sanofi’s amlitelimab, a promising treatment for moderate-to-severe atopic dermatitis (AD), has shown robust results in two global Phase 3 studies. The findings, along with a favorable safety profile, highlight its potential to improve patients’ quali
Bayer and Vanderbilt University Medical Center (VUMC) have entered a five-year collaboration to accelerate the development of new therapies for cardiovascular and kidney diseases, combining expertise in drug discovery and clinical research.
Corona Remedies Limited has secured the Eurasian Economic Union – Good Manufacturing Practices (EAEU–GMP) certification, marking a significant milestone in its global expansion. Announced on January 22, 2026, this certification allows the compa...
Max Institute of Laparoscopic Surgery, Robotic Surgery, Bariatric Surgery & GI Surgery has entered into a strategic Memorandum of Understanding (MoU) with Intuitive Surgical to accelerate the adoption of robotic-assisted surgery in India. The part...
Sun Pharmaceutical Industries has received DCGI approval for Noveltreat, a generic semaglutide injection designed to help with weight management. The treatment offers a cost-effective solution to combat obesity and related conditions.
Merck has partnered with a global health coalition to improve access to its Ebola vaccine, aiming to reduce costs and ensure availability in regions most affected by the virus. The initiative focuses on saving lives and controlling outbreaks.
Zydus Lifesciences has launched Tishtha, the world’s first biosimilar of Nivolumab in India. This launch provides cancer patients with an affordable, reliable alternative to expensive treatments, ensuring improved access to life-saving therapies.
Eli Lilly has received FDA Breakthrough Therapy designation for sofetabart mipitecan, a novel antibody-drug conjugate showing early promise for patients with platinum-resistant ovarian cancer.
Abbott has received CE Mark approval for its TactiFlex Duo Ablation Catheter in Europe, marking a major step forward in AFib treatment with dual-energy technology and successful first commercial cases.
Novavax has entered a high-value licensing deal with Pfizer, granting access to its Matrix-M adjuvant for future vaccines. The agreement brings upfront cash, milestones, and long-term royalty potential.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")